10.68

0.37% -0.04

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $10.68, with a volume of 3.96M. It is down -0.37% in the last 24 hours and down -5.24% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$10.72

Open:

$10.72

24h Volume:

3.96M

Relative Volume:

0.88

Market Cap:

$7.62B

Revenue:

$125.68M

Net Income/Loss:

$4.81B

P/E Ratio:

1.8903

EPS:

5.65

Net Cash Flow:

$-781.21M

1W Performance:

+1.14%

1M Performance:

-5.24%

6M Performance:

-9.41%

1Y Performance:

-7.45%

1-Day Range:

$10.67

$10.86

1-Week Range:

$10.55

$10.86

52-Week Range:

$9.76

$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

441-295-5950

Address

CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11

Employee

908

Twitter

Next Earnings Date

2025-02-10

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	10.68	7.62B	125.68M	4.81B	-781.21M	5.65
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

Feb 21, 2025

Roivant Sciences appoints new Principal Accounting Officer By Investing.com - Investing.com South Africa

Feb 21, 2025

Roivant Sciences appoints new Principal Accounting Officer - Investing.com

Feb 21, 2025

Roivant Sciences Appoints New Chief Accounting Officer - TipRanks

Feb 21, 2025

Feb 20, 2025

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool

Feb 20, 2025

Feb 19, 2025

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells 227,500 Shares of Stock - MarketBeat

Feb 19, 2025

Long Term Trading Analysis for (ROIV) - Stock Traders Daily

Feb 19, 2025

Feb 18, 2025

Roivant Sciences' chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Canada

Feb 18, 2025

Roivant Sciences’ chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Nigeria

Feb 18, 2025

Roivant Sciences' chief accounting officer sells $2.37 million in shares - Investing.com India

Feb 18, 2025

Eric Venker Sells 218,041 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat

Feb 18, 2025

Feb 16, 2025

Roivant Sciences president Eric Venker sells over $4.56 million in stock - MSN

Feb 16, 2025

Feb 14, 2025

Roivant Sciences president Eric Venker sells over $4.56 million in stock By Investing.com - Investing.com South Africa

Feb 14, 2025

Roivant Sciences (NASDAQ:ROIV) Shares Gap Up After Earnings Beat - MarketBeat

Feb 14, 2025

Roivant Sciences' (ROIV) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Feb 14, 2025

Feb 13, 2025

178,853 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Elevate Capital Advisors LLC - MarketBeat

Feb 13, 2025

Roivant Sciences (NASDAQ:ROIV) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

Feb 13, 2025

Roivant Sciences: Earnings Reveal Strategic Clinical Advances - MSN

Feb 13, 2025

Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position - MSN

Feb 13, 2025

Feb 12, 2025

Roivant Sciences price target lowered to $12 from $13 at BofA - Yahoo Finance

Feb 12, 2025